Posted on June 30, 2020 by Sitemaster
Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 1 Comment »
Posted on June 26, 2020 by Sitemaster
The American Urological Association (AUA), together with the American Society for Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO), has just issued a new set of guidelines for the management of advanced prostate cancer (see here). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, biochemical, castration-resistant, guideline, hormone-sensitive, metastatic, recurrence | 8 Comments »
Posted on June 19, 2020 by Sitemaster
According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized, double-blind Phase III trial known as the IPATential150 trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, mCRPC, metastatic, PTEN, Roche, trial | Leave a comment »
Posted on June 17, 2020 by Sitemaster
A newly published commentary on the CancerNetwork web site is entitled, “Radical prostatectomy as primary treatment for prostate cancer leads to better survival.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, CRPC, metastasis, outcome, radiation, surgery | Leave a comment »
Posted on June 6, 2020 by Sitemaster
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 2 Comments »
Posted on June 1, 2020 by Sitemaster
The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
Posted on May 20, 2020 by Sitemaster
Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 1 Comment »
Posted on May 16, 2020 by Sitemaster
Yesterday evening the US Food and Drug Administration (FDA) approved rucaparib (Rubraca) for the treatment of men with BRCA1/2-mutant, metastatic, castration-resistant prostate cancer (mCRPC) who have also already been treated with androgen receptor-directed therapy and taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, castration-resistant, FDA, inhibitor, mCRPC, metastatic, PARP, Rubraca, rucaparib | 1 Comment »
Posted on April 30, 2020 by Sitemaster
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
Posted on April 29, 2020 by Sitemaster
Alas … once again we hear that the combination of androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clinically meaningful impact on the overall survival (OS) of men with metastatic, castration-resistant prostate cancer (mCRPC) compared to enzalutamide alone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab, castration-resistant, checkpoint, enzalutamide, inhibitor, mCRPC, metastatic | Leave a comment »
Posted on April 27, 2020 by Sitemaster
According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: gene, Lynparza, mCRPC, mutation, olaparib, Profound, repair | 11 Comments »
Posted on April 22, 2020 by Sitemaster
According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, Myovant, oral, relugolix | 2 Comments »
Posted on April 21, 2020 by Sitemaster
TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, dose, extent, external beam, radiation, therapy, timing | Leave a comment »
Posted on April 9, 2020 by Sitemaster
A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coronavirus, COVID-19, radiation, therapy | Leave a comment »
Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
